Federal Register / Vol. 74, No. 109 / Tuesday, June 9, 2009 / Notices 27347 

FOR FURTHER INFORMATION CONTACT: 

Patrick W. McDonough, Executive 

Director of the Joint Board for the 

Enrollment of Actuaries, 202–622–8225. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the Advisory 

Committee on Actuarial Examinations 

will meet in the Internal Revenue 

Service Building, 1111 Constitution 

Avenue, NW., Washington, DC on 

Monday, June 29, 2009, from 9 a.m. to 

5 p.m., and Tuesday, June 30, 2009, 

from 8:30 a.m. to 5 p.m. 

The purpose of the meeting is to 

discuss topics and questions which may 

be recommended for inclusion on future 

Joint Board examinations in actuarial 

mathematics and methodology referred 

to in 29 U.S.C. 1242(a)(1)(B) and to 

review the May 2009 Basic (EA–1) and 

Pension (EA–2B) Joint Board 

Examinations in order to make 

recommendations relative thereto, 

including the minimum acceptable pass 

score. Topics for inclusion on the 

syllabus for the Joint Board’s 

examination program for the November 

2009 Pension (EA–2A) Examination will 

be discussed. 

A determination has been made as 

required by section 10(d) of the Federal 

Advisory Committee Act, 5 U.S.C. App., 

that the portions of the meeting dealing 

with the discussion of questions that 

may appear on the Joint Board’s 

examinations and the review of the May 

2009 Joint Board examinations fall 

within the exceptions to the open 

meeting requirement set forth in 5 

U.S.C. 552b(c)(9)(B), and that the public 

interest requires that such portions be 

closed to public participation. 

The portion of the meeting dealing 

with the discussion of the other topics 

will commence at 1 p.m. on June 29 and 

will continue for as long as necessary to 

complete the discussion, but not beyond 

3 p.m. Time permitting, after the close 

of this discussion by Committee 

members, interested persons may make 

statements germane to this subject. 

Persons wishing to make oral statements 

must notify the Executive Director in 

writing prior to the meeting in order to 

aid in scheduling the time available and 

must submit the written text, or at a 

minimum, an outline of comments they 

propose to make orally. Such comments 

will be limited to 10 minutes in length. 

All other persons planning to attend the 

public session must also notify the 

Executive Director in writing to obtain 

building entry. Notifications of intent to 

make an oral statement or to attend 

must be faxed, no later than June 19, 

2009, to 202–622–8300, Attn: Executive 

Director. Any interested person also 

may file a written statement for 

consideration by the Joint Board and the 

Committee by sending it to the 

Executive Director: Joint Board for the 

Enrollment of Actuaries, c/o Internal 

Revenue Service, Attn: Executive 

Director SE:OPR, Room 7238, 1111 

Constitution Avenue, NW., Washington, 

DC 20224. 

Dated: May 26, 2009. 

Patrick W. McDonough, 

Executive Director, Joint Board for the 

Enrollment of Actuaries. 

[FR Doc. E9–13517 Filed 6–8–09; 8:45 am] 

BILLING CODE 4830–01–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

This is notice that on January 28, 

2009, Stepan Company, Natural 

Products Department, 100 W. Hunter 

Avenue, Maywood, New Jersey 07607, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) for registration as an importer of 

Coca Leaves (9040), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import the 

listed controlled substance for the 

manufacture of a bulk controlled 

substance for distribution to its 

customer. 

No comments, objections, or requests 

for any hearings will be accepted on any 

application for registration or reregistration to import coca leaves. As 

explained in the Correction to Notice of 

Application pertaining to Rhodes 

Technologies, 72 FR 3417 (2007), 

comments and requests for hearings on 

applications to import narcotic raw 

material are not appropriate. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances listed in schedule I or II, 

which fall under the authority of section 

1002(a)(2)(B) of the Act (21 U.S.C. 

952(a)(2)(B)) may, in the circumstances 

set forth in 21 U.S.C. 958(i), file 

comments or objections to the issuance 

of the proposed registration and may, at 

the same time, file a written request for 

a hearing on such application pursuant 

to 21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than July 9, 2009. 

This procedure is to be conducted 

simultaneously with and independent 

of the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975 

(40 FR 43745), all applicants for 

registration to import a basic class of 

any controlled substances in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: June 3, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–13353 Filed 6–8–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with Title 21 

Code of Federal Regulations (CFR), 

1301.34(a), this is notice that on March 

18, 2009, Research Triangle Institute, 

Kenneth H. Davis Jr., Hermann 

Building, East Institute Drive, P.O. Box 

12194, Research Triangle, North 

Carolina 27709, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

1-(1-Phenylcyclohexyl)pyrrolidine 

(7458).

I 

1-[1-(2-Thienyl)cyclohexy]piperidine (7470).I 

1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (7473).I